MabPlex International

MabPlex International, Ltd. is a Contract Development and Manufacturing Organization (CDMO) specializing in biologics. The company offers comprehensive services for monoclonal antibody (mAb) and antibody-drug conjugate (ADC) therapeutics, including cell line development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions. Founded in 2013, MabPlex operates from three locations: two in China (Yantai and Shanghai) and one in the US (San Diego, California). The company's facilities span over 60,000 square meters, housing nine monoclonal antibody Drug Substance production lines, two Antibody-drug Conjugate Drug Substance production lines, and formulation lines for both mAb and ADC products. MabPlex's services are designed to accelerate clinical trials and support market launches for its clients.

In September 2018, MabPlex inaugurated its M2 manufacturing facility in Yantai, China, expanding its total manufacturing operations to approximately 750,000 square feet, with 400,000 square feet dedicated to cGMP execution. The M2 facility features six independent cell culture suites, each capable of supporting up to two single-use bioreactors with volumes up to 2,000 liters, four independent purification suites, and a cGMP warehouse. In February 2020, MabPlex further expanded its capabilities by launching two new 2,000-liter cell culture production lines, with plans to add two more by the end of March 2020. This expansion demonstrated the company's experience in operating different types of reactors and its ability to meet diverse customer demands flexibly.